Results 281 to 290 of about 38,812 (326)
Some of the next articles are maybe not open access.

Antiemetic agents

Current Opinion in Oncology, 1992
Despite major progress in the treatment of chemotherapy-induced emesis, nearly one third of patients undergoing cisplatin-based regimens still experience emesis within the first 24 hours of chemotherapy. An adequate treatment of delayed and anticipatory emesis remains to be determined.
openaire   +2 more sources

Which Antiemetic?

Journal of Palliative Care, 1993
The choice of antiemetic should not be arbitrary, but should be based on knowledge of the different pathways of the various stimuli that lead to nausea and vomiting and the neuroreceptors involved. The steps to be taken in choosing an appropriate antiemetic are described.
openaire   +2 more sources

Corticosteroids as Antiemetics

1988
Although several antiemetic agents can exert some control of cancer chemotherapy-related nausea and vomiting, none is totally effective. As in many other instances of medical treatment, combinations of drugs will probably prove the best means of controlling the situation.
openaire   +3 more sources

Methodology of trials with antiemetics

Supportive Care in Cancer, 1996
Chemotherapy-induced nausea and vomiting can today be controlled with the "new" antiemetics or with their various combinations in a high percentage of patients. Despite this, for some subgroups of patients, certain chemotherapy regimens and some aspects of the phenomenon (delayed presentation), emesis remains a critical problem.
Enzo Ballatori   +3 more
openaire   +3 more sources

MASCC antiemetics in advanced cancer updated guideline

Supportive Care in Cancer, 2021
Mellar Davis   +7 more
semanticscholar   +1 more source

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

Journal of Clinical Oncology, 2003
PURPOSE This analysis evaluated whether the antiemetic efficacy of the NK1 receptor antagonist aprepitant (EMEND trade mark, Merck, Whitehouse Station, NJ) plus standard antiemetics could be sustained for up to six cycles of cisplatin-based chemotherapy.
R. D. Wit   +8 more
semanticscholar   +1 more source

Use of granisetron in patients refractory to previous treatment with antiemetics.

Anti-Cancer Drugs, 1998
A multicenter, open-label, compassionate-use trial studied the antiemetic efficacy and tolerability of granisetron in patients who had failed other antiemetic therapies in previous cycles of cytostatic chemotherapy.
J. Carmichael   +5 more
semanticscholar   +1 more source

Efficacy and safety of antiemetics

Cancer Treatment Reviews, 1994
Of all the adverse effects associated with cancer chemotherapy, patients find nausea and vomiting the most distressing (I, 2). Indeed, nausea and vomiting continue to be critical problems in cancer chemotherapy. They can lead to a dramatic deterioration of the patients’ quality of life and result in up to 50% of patients delaying or missing treatment ...
Michel Marty, Volker Diehl
openaire   +3 more sources

Antiemetics, Akathisia, and Pregnancy

Psychosomatics, 2007
Gastrointestinal disorders are common in pregnant women. These disorders are often treated with antiemetic medications that block central dopaminergic neurotransmission. Dopamine antagonists can cause akathisia. Hormonal changes and other factors may place pregnant women at increased risk for the development of severe antiemetic-induced akathisia.
openaire   +2 more sources

Myths of antiemetic administration

Cancer Nursing, 1989
Chemotherapy as a treatment modality for cancer has dramatically improved outcomes for patients. However, to attain therapeutic benefit, side effects and toxicities must be endured. Among the most frequent and distressing side effects are nausea and vomiting. The experience of nausea and vomiting may become so devastating that patients will discontinue
openaire   +2 more sources

Home - About - Disclaimer - Privacy